Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05604365 · ClinicalTrials.gov registry record · NA
FearLess in Cognitively Intact Patients With Glioma
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT05604365: Completed NA study, sponsored by Virginia Commonwealth University.
NCT05604365 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05604365, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will assess the preliminary feasibility and acceptability of FearLess, a newly-developed psychological intervention for fear of cancer recurrence (FCR) among cognitively-intact patients with glioma.
Primary Outcome
As evidenced by the number of patients and caregivers that enroll in the trial
Interventions
- BEHAVIORAL FearLess Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2023-11-14 |
| Phase | NA |
What the finished NCT05604365 record still lists
NCT05604365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which FearLess Intervention is the first listed.
NCT05604365 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05604365 about?
NCT05604365 is a clinical study titled "FearLess in Cognitively Intact Patients With Glioma". This study will assess the preliminary feasibility and acceptability of FearLess, a newly-developed psychological intervention for fear of cancer recurrence (FCR) among cognitively-intact patients with glioma.
What is the current status of trial NCT05604365?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2022-11-07. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT05604365?
The interventions under investigation include: FearLess Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05604365?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05604365's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI